Modern Solutions for Opioid Use Disorder
Spark Biomedical, a prominent leader in wearable neurostimulation technology, is paving the way toward innovative treatment methods for individuals grappling with opioid use disorder. The company recently achieved a significant milestone by completing enrollment for its pivotal clinical trial aimed at boosting treatment retention among adults suffering from this challenging condition. This important undertaking has received funding from the National Institute on Drug Abuse (NIDA) as part of the HEAL Initiative, showcasing a concerted effort to address the current opioid crisis affecting many communities.
The Urgent Need for Effective Intervention
As statistics reveal that over 70% of those facing opioid use disorder experience relapse, the urgency for effective treatment alternatives has reached a critical level. The rising prevalence of synthetic opioids like fentanyl, which have contributed to alarming overdose numbers, accentuates the necessity for game-changing interventions. Spark Biomedical's groundbreaking study focuses on the use of wearable transcutaneous auricular neurostimulation (tAN) therapy as a unique strategy to support individuals in both immediate and prolonged recovery phases. Moreover, the study seeks to uncover potential synergies between tAN and two recognized medications for opioid use disorder: lofexidine and XR-naltrexone.
Expert Insight into the Trial's Significance
Dr. Navid Khodaparast, Co-founder and Chief Science Officer of Spark Biomedical, expressed enthusiasm for this significant achievement. He noted, "Completing enrollment marks a critical milestone in advancing transcutaneous auricular neurostimulation as a non-invasive, drug-free therapy for opioid use disorder. This study is not just about evaluating the effectiveness of this innovative therapy; it also delves into how it may work in tandem with established pharmacological treatments. This could offer patients a more holistic approach to their recovery journey."
Collaborative Partnership for Greater Impact
Both the Hazelden Betty Ford Foundation and Gaudenzia, key partners in the trial, have underscored the trial's vital importance. Alta DeRoo, M.D., Chief Medical Officer of the Hazelden Betty Ford Foundation, stated, "This pivotal trial represents non-pharmaceutical options for treating opioid withdrawal and empowers patients with more choices in their recovery. The collaboration emphasizes our commitment to innovative research that can combat the urgent public health challenge of opioid addiction."
Beyond Data: A Breakthrough for Treatment Engagement
Dr. Bhavani Raghavan Lobo, Psy.D., Chief Research Officer at Gaudenzia, also emphasized the transformative nature of the study. He remarked, "This trial signifies more than mere data collection; it represents a breakthrough in our approach to maintaining patient engagement in treatment for opioid use disorder. We are honored to have coordinated these efforts and are proud of the trust participants have placed in our care. This research underscores the necessity of investing in innovative, science-backed solutions to effectively address the national overdose crisis."
A Step Toward the Future
The outcomes of this research hold the promise of contributing to a forthcoming FDA submission and signal a pivotal advance in creating drug-free solutions for individuals battling opioid use disorder. This study not only sets the foundational work for potentially revolutionizing treatment methodologies but also inspires hope and potential recovery for countless individuals.
About Gaudenzia
Gaudenzia, Inc. stands as one of the largest nonprofit providers dedicated to treating individuals with substance use and co-occurring disorders across the United States. With a network of 51 facilities in areas including Pennsylvania and Maryland, Gaudenzia serves approximately 15,000 individuals annually, offering a comprehensive array of programs tailored to meet diverse needs.
About the Hazelden Betty Ford Foundation
The Hazelden Betty Ford Foundation, a leading nonprofit providing comprehensive behavioral health care, harnesses scientific research and the power of personal experience to offer healing and hope. Established in 1949, the foundation's expansive network encompasses treatment centers nationwide, alongside a robust commitment to research, education, and community support initiatives.
About Spark Biomedical
Spark Biomedical, Inc. is at the forefront of medical device innovation, dedicated to harnessing the power of bioelectronic medicine. By developing wearable neurostimulation treatments across various health fields, including behavioral health and chronic pain management, Spark aims to empower healthcare providers with more effective solutions for complex care needs. Backed by both federal and private funding, Spark Biomedical is committed to enhancing the future of patient care.
Frequently Asked Questions
What is the primary focus of Spark Biomedical's recent trial?
The trial aims to improve treatment retention for adults with opioid use disorder through wearable neurostimulation technology.
What innovative therapy is being studied in the trial?
The study investigates the use of transcutaneous auricular neurostimulation (tAN) therapy as a non-invasive treatment method.
Which medications are being explored alongside tAN therapy?
The trial examines the potential effects of tAN in combination with lofexidine and XR-naltrexone.
What milestones does Spark Biomedical hope to achieve with the trial?
The outcomes are expected to contribute towards an anticipated FDA submission, marking a step forward for drug-free treatment options.
How can individuals seeking help connect with Gaudenzia?
Individuals can contact Gaudenzia’s Treatment and Referral HelpLine at 833-976-HELP (4357) for assistance.
